Profil
Halvor Jaeger was Chief Executive Officer of Akela Pharma, Inc. In 1979, he founded LAB in Germany and served as its Chief Executive Officer.
He started his scientific career at the University of Ulm in Germany.
In 1996, he was appointed a Fellow of the American College of Clinical Pharmacology.
He acted as Expert Agréé for the French Health Authorities in pharmacokinetics.
Mr. Jaeger received an MD from the University of Ulm in Germany in 1976.
Anciens postes connus de Halvor Jaeger
| Sociétés | Poste | Fin |
|---|---|---|
| THALLION PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 09/06/2009 |
Akela Pharma, Inc.
 Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | President | 06/11/2008 |
LAB International, Inc.
 LAB International, Inc. Pharmaceuticals: MajorHealth Technology LAB International (LAB Pharma and LAB Research) is an integrated drug development company. LAB Pharma is focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies | President | 13/07/2007 |
Formation de Halvor Jaeger
| Universität Ulm | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
LAB International, Inc.
LAB International, Inc. Pharmaceuticals: MajorHealth Technology LAB International (LAB Pharma and LAB Research) is an integrated drug development company. LAB Pharma is focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies | Health Technology |
Akela Pharma, Inc.
Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | Health Technology |
Thallion Pharmaceuticals, Inc.
 Thallion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thallion Pharmaceuticals, Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its products are Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections and TLN-4601, a proprietary first in class small molecule with potential efficacy in multiple oncology indications. The company was founded in January 1998 and is headquartered in Dorval, Canada. | Health Technology |
